

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA BIOTECH SERVICES HOLDINGS LIMITED

中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

RESIGNATION OF NON-EXECUTIVE DIRECTOR AND APPOINTMENT OF EXECUTIVE DIRECTOR

The Board announces that, with effect from 5 December 2022,

- (1) Mr. Wang Zheng has resigned as a non-executive Director; and
- (2) Ms. Chui Hoi Yam has been appointed as an executive Director.

The board (the “**Board**”) of directors (the “**Directors**”, and each a “**Director**”) of China Biotech Services Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that with effect from 5 December 2022, Mr. Wang Zheng (“**Mr. Wang**”) has resigned as a non-executive Director and Ms. Chui Hoi Yam (徐海音) (alias 徐海瑛) (former name: 徐海英) (“**Ms. Chui**”) has been appointed as an executive Director.

(1) Resignation of non-executive Director

Mr. Wang has resigned as a non-executive Director with effect from 5 December 2022 due to his intention to devote more time on his other business engagements.

Mr. Wang has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). The Board would like to take this opportunity to express its gratitude to Mr. Wang for his valuable contribution to the Company during his tenure of service.

(2) Appointment of executive Director

Ms. Chui has been appointed as an executive Director with effect from 5 December 2022.

The biographical details of Ms. Chui are set out below:

Ms. Chui, aged 55, was a president of Harbin Pharmaceutical Group Co., Ltd.* (哈藥集團股份有限公司) (“**Harbin Pharmaceutical**”), a company listed on the Shanghai Stock Exchange (stock code: 600664), from March 2019 to May 2022 and was a director of Harbin Pharmaceutical from January 2021 to May 2022, where she was responsible for the overall business operation. Ms. Chui has previously worked in China Hewlett-Packard Co., Ltd. and Novartis International.

Ms. Chui received her bachelor’s degree in Economic Administration and master’s degree in Finance from Peking University, the People’s Republic of China in July 1990 and July 2001, respectively.

Pursuant to the letter of appointment made between Ms. Chui and the Company, Ms. Chui has been appointed for a term of three years commencing from 5 December 2022 and is subject to retirement by rotation and re-election and other related provisions as stipulated in the bye-laws of the Company and the Rules Governing the Listing of Securities on GEM of the Stock Exchange (the “**GEM Listing Rules**”). Pursuant to the bye-laws of the Company, Ms. Chui shall hold office until the first annual general meeting of the Company after her appointment and shall then be eligible for re-election at the meeting and thereafter, shall be subject to retirement by rotation at least once every three years. Ms. Chui is entitled to a director’s fee of HK\$50,000 per month, which was determined by the Board on the recommendation of the remuneration committee of the Company with reference to her duties and responsibilities, as well as the prevailing market conditions. She is also entitled to discretionary bonus and share options under share options scheme to be determined by the Board with reference to her performance and the performance of the Group.

As at the date of this announcement, save as disclosed above, Ms. Chui (i) does not hold any directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years, or any other major appointments and professional qualifications; (ii) does not hold any other positions with the Company or other members of the Group; (iii) does not have any relationship with any Directors, senior management, substantial or controlling shareholders (having the meaning ascribed to it in the GEM Listing Rules) of the Company; (iv) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (v) has not been involved in any of the matters as mentioned under Rules 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules.

* For identification purpose only

Save as disclosed in this announcement, there is no further information to be disclosed pursuant to the requirements of Rule 17.50(2) of the GEM Listing Rules and there are no other matters relating to the appointment of Ms. Chui that need to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to welcome Ms. Chui to join the Board as an executive Director.

By order of the Board
China Biotech Services Holdings Limited
Liu Xiaolin
Chairman and Executive Director

Hong Kong, 5 December 2022

As at the date of this announcement, the Board comprises four executive Directors, namely, Mr. Liu Xiaolin (Chairman), Mr. He Xun, Mr. Huang Song and Ms. Chui Hoi Yam; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Ho Ivan Chun Kit and Mr. Qian Hongji.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.